Verdant PhytoMed — Appendices

A detailed monthly cash flow projection for Year 1 is available upon request and will be provided as part of the investor data room documentation.

Verdant PhytoMed (Pty) Ltd Business PlanSection 16 › Appendices

Section 16 · Business Plan

Appendices

A detailed monthly cash flow projection for Year 1 is available upon request and will be provided as part of the investor data room documentation.

Appendix A: Glossary of Terms

Term Definition
API Active Pharmaceutical Ingredient
B-BBEE Broad-Based Black Economic Empowerment
CAGR Compound Annual Growth Rate
CBD Cannabidiol
COA Certificate of Analysis
DALRRD Department of Agriculture, Land Reform and Rural Development
EBITDA Earnings Before Interest, Tax, Depreciation and Amortisation
EIA Environmental Impact Assessment
EPC Engineering, Procurement and Construction
EU-GMP European Union Good Manufacturing Practice
FOB Free on Board (Incoterms)
GACP Good Agricultural and Collection Practice
GC-MS Gas Chromatography–Mass Spectrometry
HPLC High Performance Liquid Chromatography
IFRS International Financial Reporting Standards
IRR Internal Rate of Return
JSE Johannesburg Stock Exchange
NPV Net Present Value
SAHPRA South African Health Products Regulatory Authority
SAPS South African Police Service
THC Tetrahydrocannabinol
WACC Weighted Average Cost of Capital

Appendix B: Detailed Monthly Cash Flow — Year 1

A detailed monthly cash flow projection for Year 1 is available upon request and will be provided as part of the investor data room documentation.

Appendix C: Letters of Intent

Copies of signed letters of intent from prospective offtake partners are available for review under non-disclosure agreement in the investor data room.

Appendix D: Management CVs

Detailed curriculum vitae for all directors, key management personnel, and advisory board members are available in the investor data room.

Appendix E: Facility Design Drawings

Preliminary architectural and engineering drawings for the greenhouse facility and GMP processing plant are available for review in the investor data room.

This document contains proprietary and confidential information. Distribution without written consent is prohibited.